Key clinical point: Risks of atrial fibrillation (AFib) and major adverse cardiovascular events (MACE) were not substantially different between patients starting ustekinumab and those starting tumor necrosis factor inhibitors.

Major finding: Incidence rates for AFib were 5.0 and 4.1 per 1,000 person-years in the ustekinumab and tumor necrosis factor inhibitor groups, respectively (adjusted hazard ratio, 1.08; 95% CI, 0.76-1.54). Similar results were reported for MACE.

Study details: A retrospective cohort study of two commercial insurance databases including more than 60,000 adult patients with psoriatic disease.

Disclosures: The study was supported by the division of pharmacoepidemiology and pharmacoeconomics at Brigham and Women’s Hospital. Several authors reported financial relationships with pharmaceutical companies marketing biologics for psoriasis and psoriatic arthritis.